The Problem: A Diagnosis That Forces Fast, Expensive Decisions

According to the International Agency for Research on Cancer, roughly 180,000 people worldwide are diagnosed with multiple myeloma each year. In the United States alone, the American Cancer Society estimates about 36,000 new cases annually. The five-year relative survival rate has climbed past 55% — up from roughly 25% two decades ago — largely because of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

That progress comes with a bill. A standard triplet regimen in the US can run $15,000 to $25,000 per month before transplant. Autologous stem cell transplant adds $150,000 or more at a US academic center. Many patients on Medicare or private insurance still hit six-figure out-of-pocket exposure within two years.

For patients in countries with long public waitlists, the barrier is time rather than money. A six-month wait for a hematology consult in some systems means six months of uncontrolled disease.

So patients start searching. And they land on the same question: can I get the same standard of care somewhere else, faster and cheaper, without gambling on quality?

Why China Delivers Results for Myeloma Patients

China treats a very large number of myeloma patients. High-volume centers see hundreds of new cases per year, and that volume shapes everything — from how quickly a bone marrow biopsy gets read to how experienced the transplant team is. Here is what that means in practice.

Clinical Volume and Protocol Familiarity

China’s top hematology departments follow the same NCCN and IMWG guidelines used in Boston or Heidelberg. Regimens like VRd (bortezomib, lenalidomide, dexamethasone) and Dara-RVd are standard, not experimental. The difference is throughput. A department that manages several hundred myeloma patients annually develops pattern recognition that lower-volume centers simply cannot replicate.

Several Chinese centers also run investigator-initiated CAR-T trials for relapsed or refractory myeloma. China is one of the largest contributors to global CAR-T clinical research by trial count. That matters if you have already failed two or three lines of therapy.

Technology and Diagnostic Speed

The diagnostic workup for myeloma — serum protein electrophoresis, free light chain assays, FISH cytogenetics, and bone marrow biopsy — is bundled into a compressed timeline at major Chinese hospitals. What takes three to five weeks across multiple US referrals often completes in seven to ten days at a single institution. Faster staging means faster treatment start.

Imaging is equally efficient. Low-dose whole-body CT and MRI are widely available, and PET-CT can typically be scheduled within days.

Cost Without Compromise

This is the part that surprises people. Chinese drug pricing is not lower because the drugs are different. It is lower because of centralized procurement, domestic generic manufacturing, and hospital labor economics. The active molecule is the same.

Bortezomib, lenalidomide, and daratumumab are all available in China. Several are domestically produced under license or as generics, which cuts the price dramatically compared to US brand pricing.

All figures are ranges. Actual cost varies by hospital, disease stage, drug choice, and complication history. These are reference points, not quotes.

Which Chinese Hospitals Are Strongest for Myeloma?

Myeloma sits under hematology, and hematology in China is concentrated in a small number of departments. The Fudan University Hospital Rankings publish a specialty reputation list covering 45 disciplines, including hematology, with a top-10 ranking for each. That list is the most reliable public signal available.

Hospitals that consistently appear among China’s top hematology programs include Peking Union Medical College Hospital in Beijing, Ruijin Hospital in Shanghai, and West China Hospital in Chengdu. Each has a dedicated hematology department with transplant capability and active clinical trial portfolios.

Two structural notes matter here. First, the Fudan composite Top 100 list ranks hospitals by tier (A++++ down to A) rather than by specific number — so any claim of “the number one hospital in China” is marketing, not fact. Second, the specialty reputation list is where real granularity lives.

You can browse hematology and oncology rankings on our specialty rankings page, and compare hospital-by-hospital detail across our directory of 340+ top-ranked Chinese hospitals in 37 cities. If you already know you want Beijing or Shanghai, the Beijing hospital guide breaks down what each institution is known for.

What the Treatment Pathway Actually Looks Like

Myeloma care follows a predictable sequence. Knowing it in advance removes most of the anxiety.

• Confirmation and staging. Your existing biopsy and labs get reviewed. If the diagnosis is confirmed, staging uses the Revised International Staging System (RISS), which combines beta-2 microglobulin, albumin, LDH, and cytogenetics.
• Induction therapy. Most patients start a triplet or quadruplet regimen. Cycles run 21 or 28 days. Response is measured after each two to three cycles using IMWG response criteria.
• Stem cell collection and transplant. If you are eligible, stem cells are harvested after three to six cycles of induction, then high-dose melphalan and autologous transplant follow. The inpatient stay is typically two to three weeks.
• Consolidation and maintenance. Maintenance continues for years. This is where long-term cost differences become enormous.
• Relapse management. Second-line regimens, bispecific antibodies, or CAR-T depending on what you have already received.

A realistic timeline for a patient arriving with a confirmed diagnosis: one to two weeks for local re-staging, then induction starting immediately. Transplant, if indicated, usually happens three to six months in. Total in-country time for the transplant phase alone runs six to ten weeks including recovery monitoring.

How to Evaluate a Chinese Myeloma Program Before You Commit

Not every hospital that lists “hematology” is equipped for complex myeloma. Here is what separates a real program from a department that mainly handles anemia and leukemia follow-up.

• Transplant volume. Ask how many autologous transplants the department performs annually. A program doing fewer than 30 a year is not the right place for a complex case.
• Drug access. Confirm that daratumumab, carfilzomib, and pomalidomide are on the hospital formulary, not just approved nationally. Formulary status varies by institution.
• Trial availability. If you are relapsed or refractory, ask specifically about BCMA-directed therapies and CAR-T protocols currently enrolling.
• English capability. The international department, not the general ward, is where English-speaking coordination happens. General outpatient clinics at large public hospitals operate almost entirely in Chinese.

Who is this not suitable for? Patients who are medically unstable and cannot tolerate air travel. Patients whose disease is already well controlled on a regimen they can afford at home. And patients who need a transplant within four weeks — visa processing and hospital scheduling rarely compress that far.

Practical Considerations: Visa, Payment, and Follow-Up

Visa. Foreign patients coming to China for medical treatment use the S2 visa, issued for short-term medical treatment and private affairs, with the purpose of visit noted. Stays exceeding 180 days require the S1 category. Accompanying family members apply under S2 as well. The M visa is for commercial and trade activities and is not the correct category for medical travel. Requirements change — always confirm current documentation with the nearest Chinese embassy or consulate, and note that a hospital invitation letter is usually part of the application package.

Payment. Chinese public hospitals require prepayment. International credit cards are accepted at international departments but not universally at general cashier windows. Plan to wire funds in advance or carry a card confirmed as accepted. Private international hospitals often bill insurers directly; public hospitals typically require you to pay upfront and seek reimbursement from your insurer afterward.

Records. Bring your full pathology report, cytogenetic FISH panel, all imaging on disc, and a chronological list of every prior regimen with dates and responses. Without this, the Chinese team restages from zero — which costs you weeks.

Follow-up after returning home. Maintenance therapy can often continue in your home country if your local oncologist agrees to the plan. Get the Chinese team to write a clear maintenance protocol you can hand to your physician. Drug sourcing for lenalidomide may differ at home, so confirm availability before you leave.

If you want to understand the full end-to-end process — registration, admission, interpretation, and discharge — our team covers it on the patient consultation page.

Frequently Asked Questions